Neuromed

For over 30 years, research and scientific activity have been the basis of the Mediterranean Neurological Institute I.R.C.C.S. Neuromed. The structure has evolved towards a particularly avant-garde model, capable of combining translational research and clinical activity, pursuing excellence in offering highly qualified integrated services in the Neuroscience sector. Aiming to achieve this mission, the Mediterranean Neurological Institute I.R.C.C.S. Neuromed regularly participates in programs financed at regional, national and international level in collaboration with universities, organizations, research centers, IRCCS and companies. The ongoing projects are aimed at identifying the molecular and genetic basis for the diagnosis and treatment of diseases of the central and peripheral nervous system. The investments underway for the use of new technologies and the construction of new laboratories are aimed at the development of innovative diagnostic methods, the development of cutting-edge surgical techniques and to verify the therapeutic efficacy of new drugs.

In a medium-long term perspective, the Institute intends to further strengthen its strategic positioning as a primary player in the neuroscience sector, both nationally and internationally. The strengthening of the strategic positioning of the Mediterranean Neurological Institute I.R.C.C.S. Neuromed is primarily based on the further advancement of scientific research actions, not only the basic and translational ones, but above all the industrial and experimental ones to develop application segments of interest also for the industrial sector. The proposed approach aims to consolidate the integration of different disciplines, such as neuroanatomy, neurophysiology, molecular neurobiology, genetics and behavioral sciences, with physics, mathematics, nanotechnology, bioengineering, and neurorobotics. Thanks to this strong multi-disciplinary approach, Neuromed has been able to build an innovative digital imaging multimodal platform (DIMP), which is one of the EUROBIOIMAGING nodes.

Role of institution in the project

NEUROMED will focus on dynamic PET imaging, within the following tasks, covering data annotation framework for dynamic PET imaging parameters estimation (WP4),  data quality monitoring and harmonization strategies (WP5). NEUROMED will develop dedicated A.I. tools for the combined modeling of imaging data and other biomarkers, profiting of the WP5 unified data models, with specific focus in quantitative parametric dynamic Positron Emission Tomography data; dedicated A.I. models for dynamic PET data and quantitative mapping extraction (WP6). New use cases in the field of brain and lung cancer models will be developed (WP7).

Nicola D'Ascenzo

Nicola D'Ascenzo received the B.Sc. degree in physics and the M.S. degree in applied physics from the University of Pisa in 2003 and 2005, respectively, and the Ph.D. degree in natural sciences from the Physics Department, University of Hamburg. He is currently a Full Professor with the Department of Electronic Engineering and Information Science at the University of Science and Technology of China and he heads the Department of Innovation in Medical Physics and Engineering at the Istituto Neurologico Mediterraneo, NEUROMED I.R.C.C.S. After strengthening a new digital signal processing approach based on the Digital PET technology, and developing new Brain PET, Helmet PET systems and A.I.-based analysis strategies, Prof. D'Ascenzo pioneered in the last years the frontier of PET setting the theoretical, methodological, and technological fundaments for the transition from a lab-based plant PET imaging to an in-field-based agronomic Agri-PET imaging. His research is particularly devoted to kinetic modeling of PET imaging for preclinical, clinical and plant science, as well as digital technologies enabling the precise measurement of such mechanisms with high spatial and temporal resolution.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.